CN114984039A - Pharmaceutical composition for chronic wound healing and application thereof - Google Patents
Pharmaceutical composition for chronic wound healing and application thereof Download PDFInfo
- Publication number
- CN114984039A CN114984039A CN202210587089.0A CN202210587089A CN114984039A CN 114984039 A CN114984039 A CN 114984039A CN 202210587089 A CN202210587089 A CN 202210587089A CN 114984039 A CN114984039 A CN 114984039A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- wound healing
- chronic wound
- chronic
- oral ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 230000029663 wound healing Effects 0.000 title claims abstract description 27
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 28
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 208000007117 Oral Ulcer Diseases 0.000 claims abstract description 21
- 206010052428 Wound Diseases 0.000 claims abstract description 20
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- -1 2-methoxy-5-methyl-4-sulfophenyl Chemical group 0.000 claims description 11
- 239000002562 thickening agent Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 239000008119 colloidal silica Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 229910021485 fumed silica Inorganic materials 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 12
- 208000025865 Ulcer Diseases 0.000 abstract description 10
- 230000035876 healing Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 10
- 231100000397 ulcer Toxicity 0.000 abstract description 9
- 210000000214 mouth Anatomy 0.000 abstract description 7
- 208000035143 Bacterial infection Diseases 0.000 abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000004888 barrier function Effects 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 229940127554 medical product Drugs 0.000 abstract description 2
- 230000009967 tasteless effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 7
- 230000001066 destructive effect Effects 0.000 description 6
- 230000008105 immune reaction Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical group [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a pharmaceutical composition for chronic wound healing and application thereof, and belongs to the technical field of medical products, wherein the pharmaceutical composition for chronic wound healing comprises 25-35% of sulfuric acid, 30-55% of hydroxybenzenesulfonic acid and the balance of water in percentage by mass, and the pharmaceutical composition for chronic wound healing can be used for treating oral ulcer, can be used for remaining a thin precipitate after surface tissues of unhealed chronic wounds are solidified and serve as a barrier of organic substances, so that the ulcer is prevented from being further stimulated by substances in an oral cavity in the natural healing process to cause pain, and is effectively prevented from subsequent bacterial infection, tasteless and good in treatment effect.
Description
Technical Field
The invention belongs to the technical field of medical products, and particularly relates to a pharmaceutical composition for chronic wound healing and application thereof.
Background
Canker sores are an ulcerative loss condition that occurs in the mucous membranes of the mouth, often in the inner lip, tongue, soft palate, etc., where the mucous membranes lack a cornified layer or are poorly cornified. The fester necrosis part of the oral ulcer can leave yellow and white fester with a clear diameter of 2-5 mm on the surface of an organ, the fester edge can be hardened to a certain degree, and an erythema area appears around the fester edge, and the pathological change degree of the erythema area depends on the degree of secondary bacterial infection. The stomatocace has severe pain and obvious local burning pain, and causes great inconvenience to diet, speaking and daily life of patients when the stomatocace is serious; and is accompanied with symptoms such as chronic throat, halitosis, nausea, dysphoria, lymphadenectasis, etc. Canker sores are thought to be caused by viruses, and in some cases, genetics, body hormonal changes, and gastrointestinal imperfections are also contributing factors to canker sores.
In the aspect of pharmaceutical dosage forms, the main treatment modes of domestic oral ulcer at present comprise two types: one type is topical treatment, including topical tablets, powders, mouthwashes, sprays, topical gels, films, sprays, and the like; one is systemic medication, which mainly comprises oral preparations, capsules and the like. The medicine for systemic administration has slow release of the medicine effect and poor pertinence, and the long-term use of the medicine can more or less affect other organs of the human body. The tablet in the local medicine is hard, the mechanical stimulation to the wound surface is large when the tablet is applied, meanwhile, the film is difficult to be applied according to the size of ulcer, and the tablet is easy to be touched by the tongue to fall off; most of the powder and the powder spray are prepared from medicinal powder and the like, so the powder and the powder have poor taste, a protective layer is not easy to form at ulcer parts, the administration dosage at different parts is difficult to be uniform, and the treatment effect is poor; the gargle has low drug concentration, short residence time in oral cavity and low drug effect generation efficiency.
In terms of the pharmaceutical ingredients of the preparation for oral ulcer, CN 112826923a discloses a composition for oral ulcer, an oral ulcer film and a preparation method thereof. The composition comprises hyaluronic acid or its salt, ectoin, lidocaine, iodine, recombinant human epidermal growth factor, vitamin C and vitamin B2 as main ingredients. The composition is effective in relieving pain, resisting inflammation, and promoting healing. CN101444527A discloses a film agent for oral ulcer, which comprises macromolecular substances, is not added with antibacterial and anti-inflammatory substances, has no antibacterial and anti-inflammatory effects and has poor curative effect. CN101317917A discloses a buccal tablet for treating oral ulcer, which contains the main ingredients of traditional Chinese medicine and hormone, and has drug resistance and dependence after long-term use, and the buccal tablet has low administration concentration at the oral ulcer part and low drug effect generation efficiency. CN102579702A discloses a pharmaceutical composition for treating oral ulcer, the active ingredients of the pharmaceutical composition are antibacterial agent, anti-inflammatory ingredient and bee product, which can effectively relieve the symptoms and pain of oral ulcer in a short time and rapidly promote the healing of oral ulcer, but the antibacterial agent selected in the patent is silver ion or nano silver, which is not only expensive, but also has a certain risk of drug safety. CN1582172A discloses a method for treating canker sore by using oral patch to accelerate healing and relieve pain, firstly, the effective components of the oral patch are bactericide (penicillin and amoxicillin) and licorice extract, but the oral patch mainly limits local flow of saliva and needs at least 30min to apply the medicine on canker sore, and needs at least 2 hours per day, said method has the problems of low medicine administration efficiency, long application time, causing discomfort for people and easy falling off for general people.
Canker sores are caused by non-healing chronic wounds, primarily manifested as delayed healing of necrotic tissue, causing it to become a reservoir for bacterial growth, and are a major factor in promoting inflammation and cell migration. Conventional methods of treating chronic wounds are debridement, including autolytic, enzymatic, mechanical, and surgical procedures, but these conventional debridement treatments do not provide a good cure for the chronic wound, thereby causing subsequent discomfort and therapeutic distress to the patient and the physician.
Disclosure of Invention
In order to overcome the above-mentioned disadvantages of the prior art, an object of the present invention is to provide a pharmaceutical composition for chronic wound healing, which can be used for treating canker sores, can solidify and leave a thin layer of precipitate on the superficial tissues of unhealed chronic wounds, and can be used as a barrier for organic substances, so as to prevent the canker sores from being further stimulated by substances in the oral cavity during the natural healing process, and can effectively prevent subsequent bacterial infection.
The invention also aims to provide application of the pharmaceutical composition for chronic wound healing.
In order to achieve one of the purposes, the invention adopts the following technical scheme:
the pharmaceutical composition for treating oral ulcer comprises, by mass, 25-35% of sulfuric acid, 30-55% of hydroxybenzene sulfonic acid, and the balance of water.
Further, the composition also comprises 0.1-1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in percentage by mass.
Further, the coating also comprises 1-5% of a thickening agent in percentage by mass.
Further, the thickening agent is one or a composition of more than two of medical cellulose, colloidal silica, silica gel, fumed silica and liquid silica gel.
Further, the thickener comprises one or two of colloidal silica and cellulose.
In order to achieve the second purpose, the invention adopts the following technical scheme:
the invention provides application of a pharmaceutical composition for chronic wound healing, which is used for preparing a medicament for treating oral ulcer.
Further, the dosage form of the medicament for treating the oral ulcer is one of a liquid preparation, a gel preparation and a paste preparation.
Further, the viscosity of the medicine for treating the oral ulcer is 50-100000 cPs, and the acidity of the medicine for treating the oral ulcer is 7-9.5 mM/g.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention provides a pharmaceutical composition for chronic wound healing, wherein sulfuric acid and hydroxybenzene sulfonic acid in the composition firstly play a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevent damage caused by destructive inflammatory immune reaction caused by the necrotic tissues and effectively prevent a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left after superficial tissue of the unhealed chronic wound is solidified and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented; the hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in the composition is a medical dye and plays a role in coloring; the thickener in the composition mainly plays a role in film formation and thickening, and the preparation can be made into a liquid spray type or a paste coating type by adjusting the addition amount of the thickener.
(2) The invention provides the application of the pharmaceutical composition for curing the chronic wounds, which is tasteless, can be sprayed or coated on the chronic wounds of the dental ulcers, can be used for curing the dental ulcers and has good curative effect.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application more clearly and completely understood, the technical solutions of the present application will be described below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present application and are not intended to limit the present application.
Example 1
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 25% of sulfuric acid, 55% of hydroxybenzenesulfonic acid, 0.1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt and 19.9% of water in percentage by mass.
Example 2
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises, by mass, 35% of sulfuric acid, 30% of hydroxybenzenesulfonic acid, 1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of colloidal silicon dioxide, 4% of medical grade cellulose, and 29% of water.
Example 3
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 5% of colloidal silicon dioxide and 14.4% of water in percentage by mass.
Example 4
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 5% of medical grade cellulose and 14.4% of water in percentage by mass.
Example 5
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of colloidal silica and 18.4% of water in percentage by mass.
Example 6
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of medical grade cellulose and 18.4% of water in percentage by mass.
Example 7
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of silica gel, 2% of fumed silica, 2% of liquid silica gel and 14.4% of water in percentage by mass.
The sulfuric acid and the hydroxybenzene sulfonic acid in the composition firstly play a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevent damage caused by destructive inflammatory immune reaction initiated by the necrotic tissues and effectively prevent a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left after superficial tissue of the unhealed chronic wound is solidified and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented; the hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in the composition is a medical dye and plays a role in coloring; the thickener in the composition mainly plays a role in film formation and thickening, and the preparation can be made into a liquid spray type or a paste coating type by adjusting the addition amount of the thickener.
Example 8
The embodiment provides an application of a pharmaceutical composition for chronic wound healing, the pharmaceutical composition for chronic wound healing is used for preparing a pharmaceutical preparation for treating dental ulcer, the viscosity of the pharmaceutical preparation is 50-100000 cPs, the acidity of the preparation is 7-9.5 mM/g, the density of the preparation can be properly adjusted according to needs, the preparation can be made into a liquid spray type or a paste coating type for application by adjusting the addition amount of a thickening agent, and the application can be specifically determined according to the selection and the adaptability of a patient.
The application method of the pharmaceutical preparation comprises the step of spraying or coating the pharmaceutical preparation on chronic wounds of canker sores, the preparation can generate stabbing pain at the wounds, no feeling is generated after about 15 seconds, then the skin can generate a protective film through self-healing of the surface layer of a human body, the protective film can inhibit the pain after the protective film is formed, and therefore the pain time is shortened. The pharmacological action of the medicinal preparation is that the medicinal preparation firstly plays a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevents damage caused by destructive inflammatory immune reaction initiated by the necrotic tissues and effectively prevents a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left on the surface tissue of the unhealed chronic wound in a coagulation mode and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.
Claims (8)
1. The pharmaceutical composition for treating the chronic wound is characterized by comprising, by mass, 25-35% of sulfuric acid, 30-55% of hydroxybenzene sulfonic acid and the balance of water.
2. The pharmaceutical composition for chronic wound healing according to claim 1, further comprising 0.1 to 1% by mass of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt.
3. The pharmaceutical composition for chronic wound healing according to claim 1, further comprising 1-5% by mass of a thickening agent.
4. The pharmaceutical composition for chronic wound healing according to claim 1, wherein the thickening agent is one or a combination of two or more of medical grade cellulose, colloidal silica, silica gel, fumed silica, liquid silica gel.
5. A pharmaceutical composition for chronic wound healing according to claim 4, wherein said thickening agent comprises colloidal silica and medical grade cellulose.
6. The use of the pharmaceutical composition for chronic wound healing according to claims 1 to 5, wherein the pharmaceutical composition for chronic wound healing is used for preparing a medicament for treating oral ulcer.
7. The use of a pharmaceutical composition for chronic wound healing according to claim 6, wherein the medicament for treating oral ulcer is in a dosage form of one of liquid preparation, gel preparation and paste preparation.
8. The use of a pharmaceutical composition for chronic wound healing according to claim 6, wherein the medicament for treating oral ulcer has a viscosity of 50 to 100000cPs, and the acidity of the medicament for treating oral ulcer is 7 to 9.5 mM/g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210587089.0A CN114984039A (en) | 2022-05-26 | 2022-05-26 | Pharmaceutical composition for chronic wound healing and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210587089.0A CN114984039A (en) | 2022-05-26 | 2022-05-26 | Pharmaceutical composition for chronic wound healing and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114984039A true CN114984039A (en) | 2022-09-02 |
Family
ID=83028780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210587089.0A Pending CN114984039A (en) | 2022-05-26 | 2022-05-26 | Pharmaceutical composition for chronic wound healing and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114984039A (en) |
-
2022
- 2022-05-26 CN CN202210587089.0A patent/CN114984039A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105142728B (en) | Compositions and methods for treating surface wounds | |
CN108135972B (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
US20210000759A1 (en) | Cannabinoid and menthol compositions and methods | |
EP3164139B1 (en) | Topical compositions and methods for treating wounds | |
AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
CN108159024B (en) | Sustained-release patch for treating oral ulcer and preparation method thereof | |
JP2010163451A (en) | Oral patch including licorice root extract for treating ulcer | |
CN108210689A (en) | A kind of canker sore film containing hyaluronic acid and preparation method thereof | |
US4708873A (en) | Method of chemically debriding uncerated necrotic tissue | |
CN105125445A (en) | Toothpaste composition | |
CN109481527B (en) | Traditional Chinese medicine composition for preventing or treating oral diseases and application thereof | |
US20210220292A1 (en) | Cannabinoid and anesthetic compositions and methods | |
CN110151786B (en) | Application of nano carbon particles in preparation of medicine for treating oral ulcer and medicine | |
CN114984039A (en) | Pharmaceutical composition for chronic wound healing and application thereof | |
CN102552734B (en) | Gargle for treating dental ulcer | |
CN111803622A (en) | Liquid repairing film for oral ulcer | |
CN111000871A (en) | Oral cavity spray and preparation method thereof | |
CN111110831A (en) | Ulcer paste and preparation method thereof | |
CN100356910C (en) | Medicine composition for treating beriberi | |
CN118649226A (en) | Application of recombinant mussel mucin in preparation of product for relieving oral wound pain | |
CN111358927B (en) | Pujiang medicinal composition and application thereof | |
CN111329881A (en) | Oral ulcer film and preparation method and application thereof | |
CN110652501A (en) | Preparation method of propolis traditional Chinese medicine adhesive tablet with double-layer structure for oral cavity | |
WO2022218136A1 (en) | Use of adenine in preparation of drug for treating diabetic ulcers | |
CN115590863A (en) | Ointment for treating scald, hemorrhoid, anal fissure and hand and foot chap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |